Exceptional long term response to crizotinib in ROS 1‐postive advanced non small cell lung cancer

Abstract Non‐small‐cell lung cancer (NSCLC) accounts for the majority of lung cancer cases worldwide, with a significant proportion of patients harbouring actionable oncogenic alterations. Among these alterations, the ROS1 rearrangement represents a distinct subset with therapeutic implications. Her...

Full description

Bibliographic Details
Published in:	Respirology Case Reports
Main Authors:	Anjali Murali, Anju Farsana A, Sobha Subramaniam, Malini Eapen, Indu R. Nair, Keechilat Pavithran
Format:	Article
Language:	English
Published:	Wiley 2024-09-01
Subjects:	actionable genomic alterations crizotinib non‐small‐cell lung cancer prolonged PFS ROS1 rearrangement
Online Access:	https://doi.org/10.1002/rcr2.70033

Similar Items

Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence
by: Yurong Wang, et al.
Published: (2022-12-01)

Clinical Efficacy of Crizotinib as the First-Line Therapy of Advanced Non-Small-Cell Lung Carcinoma with ROS-1 Rearrangement: A Systematic Review
by: Muhamad Rizqy Fadhillah, et al.
Published: (2023-06-01)

A case of ROS1‐rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib
by: Hiroaki Tachi, et al.
Published: (2020-07-01)

Identification of a novel ALK variant intrinsically resistant to crizotinib
by: Ullas Batra, et al.
Published: (2020-12-01)

Crizotinib-Related Aseptic Abscesses in Lung Adenocarcinoma and <i>ROS1</i>-Gene Rearrangement: A Case Report
by: Thamires Oliveira-Silva, et al.
Published: (2025-01-01)

Fatal interstitial lung disease associated with Crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: a case report
by: Shibo Wu, et al.
Published: (2018-07-01)

Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort
by: Amanda J. W. Gibson, et al.
Published: (2022-03-01)

Case Report: Malignant peritoneal mesothelioma with TFG-ROS1 fusion responds to crizotinib
by: Wei Ye, et al.
Published: (2025-10-01)

First‐line crizotinib versus platinum‐pemetrexed chemotherapy in patients with advanced ROS1‐rearranged non‐small‐cell lung cancer
by: Lan Shen, et al.
Published: (2020-05-01)

Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study
by: Alper Topal, et al.
Published: (2025-03-01)

Non‐small cell lung cancer with mesenchymal–epithelial transition gene exon 14 skipping mutation treated with crizotinib
by: Seigo Katakura, et al.
Published: (2019-10-01)

Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib
by: Bjoern Bielec, et al.
Published: (2020-03-01)

Crizotinib resistance: BRAF mutation implications for therapeutic strategies
by: Li Xie
Published: (2021-01-01)

Crizotinib resistance conferred by BRAF V600E mutation in non–small cell lung cancer harboring an oncogenic ROS1 fusion
by: Shuang Ren, et al.
Published: (2021-01-01)

Case report: complete remission with crizotinib in ROS1 fusion-positive sinonasal mucosal melanoma
by: Jun Cao, et al.
Published: (2022-10-01)

Prolonged survival without progression under crizotinib treatment
by: Ahmet Gulmez, Dr.
Published: (2020-01-01)

Influence of alectinib and crizotinib on ionizing radiation - in vitro analysis of ALK/ROS1-wildtype lung tissue cells
by: Tina Jost, et al.
Published: (2022-05-01)

Real-world studies of crizotinib in patients with ROS1-positive non-small-cell lung cancer: experience from China
by: Hua Zhong, et al.
Published: (2024-12-01)

Isotopic Radiolabeling of Crizotinib with Fluorine-18 for In Vivo Pet Imaging
by: Malvika Sardana, et al.
Published: (2022-12-01)

Clinical Efficacy of Crizotinib in Advanced ALK Positive  Non-small Cell Lung Cancer
by: Jing ZHAO, et al.
Published: (2015-10-01)

TARGETED THERAPY OF LUNG CANCER WITH THE ROS1 REARRANGEMENT
by: K. K. LAKTIONOV, et al.
Published: (2017-06-01)

Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC
by: Yi-Long Wu, MD, et al.
Published: (2022-10-01)

Use of crizotinib for refractory ALK-positive lymphomas
by: L N Shelikhova, et al.
Published: (2017-07-01)

Interaction between crizotinib and tropifexor through in vitro and in vivo studies
by: An Shen, et al.
Published: (2025-10-01)

Association of anticoagulant use with clinical outcomes from crizotinib in ALK‐ and ROS1‐rearranged advanced non‐small cell lung cancers: A retrospective analysis of PROFILE 1001
by: Terry L. Ng, et al.
Published: (2022-12-01)

Successful Crizotinib Rechallenge after Crizotinib-Induced Organizing Pneumonia in Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer
by: Nobuhiro Asai, et al.
Published: (2014-09-01)

Crizotinib Treatment Combined with Resection and Whole-brain Radiation Therapy  in A ROS1 Rearranged Lung Adenocarcinoma with Brain Metastasis:  Case Report and Literature Review
by: Min ZHANG, et al.
Published: (2016-08-01)

Development of 10-Hydroxycamptothecin-crizotinib conjugate based on the synergistic effect on lung cancer cells
by: Zhen Liu, et al.
Published: (2023-12-01)

Association of PD-L1 expression and clinical outcomes in ROS1 - rearranged advanced non-small cell lung cancer treated with crizotinib
by: Huixian Zhang, et al.
Published: (2024-05-01)

Front‐line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control
by: Shih‐Hao Huang, et al.
Published: (2019-12-01)

Case report: Durable response of immuno-chemotherapy targeting a rare ROS1 fusion-positive extensive-stage SCLC patient after primary resistance to crizotinib
by: Mengli Qiu, et al.
Published: (2025-04-01)

Renal Abscess Caused by Crizotinib: A Rare Case Report
by: Zhaojun Wan, et al.
Published: (2022-07-01)

Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature
by: Peng Zhang, et al.
Published: (2024-04-01)

Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China
by: Zihua Zou, et al.
Published: (2022-01-01)

Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center
by: Chang Liu, et al.
Published: (2019-10-01)

Disturbing Cholesterol/Sphingolipid Metabolism by Squalene Epoxidase Arises Crizotinib Hepatotoxicity
by: Hao Yan, et al.
Published: (2025-04-01)

Clinical Research of Crizotinib in Advanced Non-small Cell Lung Cancer
by: Haibo ZHU, et al.
Published: (2013-06-01)

Case report: ALK-positive histiocytosis presented as bilateral synchronous breast masses with long-term remission on crizotinib
by: Yuhang Zhou, et al.
Published: (2023-11-01)

Gastric cancer patient with c-MET amplification treated with crizotinib after failed multi-line treatment: A case report and literature review
by: Guoxin Hou, et al.
Published: (2019-06-01)

Crizotinib: A comprehensive review
by: Arvind Sahu, et al.
Published: (2013-01-01)